Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis
Rev. Soc. Bras. Med. Trop
;
28(4): 405-7, Oct.-Dec. 1995.
Article
in English
| LILACS
| ID: lil-187131
RESUMO
The authors report a case of a male patient from Bacabal, MA with diffuse cutaneous leishmaniasis (DCL), for at least nine years, with 168 lesions on his body. These were tumour-like nodules with some ulceration. He used pentavalent antimonial (glucantime) and an association of gamma interferon plus glucantime with improvement of the lesions but relapsed later. Recently, pentamidine isethionate (pentacarinat) was given a dosage of 4mg/kg/weight/day on alternate days for 20 applications. After 3 months a similar course of 10 application was given 2 times. Later he developed diabetic signs with weight loss of 10kg, polydypsia, polyuria and xerostomia. The lower limbs lesions showed signs of activity. Blood glucose levels normalised and remain like this at moment. Attention is drawn to the fact that pentamidine isethionate should be used as a therapy option with care, obeying rigorous laboratory controls including a glucose tolerance test.
Search on Google
Index:
LILACS (Americas)
Main subject:
Pentamidine
/
Leishmaniasis, Diffuse Cutaneous
/
Diabetes Mellitus
/
Antiprotozoal Agents
Type of study:
Risk factors
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
Tropical Medicine
Year:
1995
Type:
Article
Similar
MEDLINE
...
LILACS
LIS